Skip to content

Efficacy and Safety of Sublingual Immunotherapy (SLIT)

A Multicenter Randomized DBPC Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy (SLIT) With Allergen Extracts From Pollen in Patients With Seasonal Allergic Rhinitis

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01012882
Enrollment
120
Registered
2009-11-13
Start date
2016-11-30
Completion date
2017-11-30
Last updated
2015-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Brief summary

The purpose of this study is to evaluate the efficacy and safety of specific sublingual immunotherapy (SLIT) with allergen extracts in patients suffering from seasonal allergic rhinitis .

Interventions

BIOLOGICALsublingual immunotherapy with allergen extract

sublingual application

BIOLOGICALsublingual immunotherapy with placebo

sublingual application

Sponsors

Roxall Medizin
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Positive history of allergen specific seasonal allergic rhinitis * Positive screening skin prick test (wheal diameter \> 3 mm) * Compliance and ability of the patient to complete a Diary Card for self-evaluating of the symptoms and antisymptomatic medication * Signed and dated patient´s Informed Consent,

Exclusion criteria

* Previous immunotherapy within the last 3 years, * Simultaneous participation in other clinical trials, * Other reasons contra-indicating an inclusion into the trial according to the investigator´s estimation (e.g. poor compliance), * Auto-immune disorders, * Severe chronic inflammatory diseases, * Malignancy, * Alcohol abuse, * Existing or intended pregnancy, lactation and/or lack of adequate contraceptive protection, * Treatment with beta-blockers (incl. local application) and/or other contra-indicated drugs.

Design outcomes

Primary

MeasureTime frame
Symptom and medication score1 year

Secondary

MeasureTime frame
Safety of the treatment1 year
Documentation of adverse events1 year
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)1 year
Clinical global improvement1 year

Countries

Germany

Contacts

Primary ContactRoxall Medizin
info@roxall.de0049408972520

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026